GlassScriptPhysician profile
Gary W Price
NPI 1811968936
$23,016.08
in general payments reported to CMS, 2019-2025
34 companies · $3,505 in 2025
The $3,505 reported for 2025 was more than what 79% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,755 · 2020: $2,162 · 2021: $2,644 · 2022: $2,716 · 2023: $2,945 · 2024: $3,288 · 2025: $3,505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,199 · Consulting Fee: $288 · Education: $251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,199.49 |
| Consulting Fee | $287.92 |
| Education | $251.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $4,402.00 | 2019-2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $2,862.08 | 2020-2025 | Cuvitru, Takhzyro, Hyqvia |
| Astrazeneca Pharmaceuticals LP | $2,111.51 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Csl Behring | $1,849.57 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Glaxosmithkline, LLC. | $1,639.31 | 2019-2025 | Trelegy Ellipta, Nucala, Shingrix |
| Octapharma USA, INC. | $1,443.85 | 2019-2025 | Cutaquig, Panzyga |
| Regeneron Healthcare Solutions, INC. | $1,114.62 | 2020-2025 | Dupixent |
| Pfizer INC. | $924.67 | 2019-2025 | |
| Kaleo, INC. | $868.03 | 2019-2024 | Auvi-Q |
| Grifols USA, LLC | $840.11 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Pharming Healthcare, INC. | $741.21 | 2019-2025 | Ruconest |
| Optinose US, INC. | $511.29 | 2019-2025 | |
| Amgen INC. | $491.72 | 2022-2025 | Tezspire |
| Teva Pharmaceuticals USA, INC. | $451.98 | 2019-2023 | Airduo Digihaler |
| Adma Biomanufacturing LLC | $394.00 | 2022-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $382.54 | 2019 | |
| Novartis Pharmaceuticals Corporation | $350.40 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $345.65 | 2019-2022 | |
| Genzyme Corporation | $331.56 | 2019-2021 | |
| Ars Pharmaceuticals Operations, INC. | $198.84 | 2025 | Neffy |
| Incyte Corporation | $168.17 | 2024-2025 | Opzelura |
| Hikma Pharmaceuticals USA | $120.19 | 2023-2025 | Ryaltris |
| Genentech, INC. | $93.60 | 2022 | |
| Ionis Pharmaceuticals, INC. | $93.39 | 2025 | Dawnzera |
| Sanofi-Aventis U.S. LLC | $55.62 | 2019-2021 | |
| Leo Pharma INC. | $46.01 | 2023 | Adbry |
| Kedrion Biopharma, INC. | $32.12 | 2025 | Albuked, Gammaked, Rhogam Ultra-Filtered Plus |
| Lilly USA, LLC | $25.26 | 2025 | Ebglyss |
| Biocryst US Sales Co., LLC | $23.95 | 2021 | |
| Eyevance Pharmaceuticals LLC | $21.75 | 2020 | |
| Arcutis Biotherapeutics, INC. | $20.81 | 2025 | Zoryve |
| Merck Sharp & Dohme LLC | $20.73 | 2025 | Capvaxive, Vaxneuvance |
| Organon LLC | $19.81 | 2025 | Nexplanon |
| Circassia INC. | $19.73 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Price listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.